XM does not provide services to residents of the United States of America.

U.S. STOCKS Chewy, Abercrombie & Fitch, Kohl's



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-U.S. STOCKS ON THE MOVE-Chewy, Abercrombie & Fitch, Kohl's</title></head><body>

Eikon search string for individual stock moves: STXBZ

The Day Ahead newsletter: https://refini.tv/3LI4BU7

The Morning News Call newsletter: https://refini.tv/3dKUyB8

Wall Street's main indexes were set for a muted open on Wednesday ahead of Nvidia's earnings report, with focus squarely on if the recent bull market rally that was led by the AI chip firm and other tech-related shares can be sustained. .N


At 9:01 ET, Dow e-minis 1YMc1 were down 0.07% at 41,329. S&P 500 e-minis ESc1 were down 0.05% at 5,641.75, while Nasdaq 100 e-minis NQc1 were down 0.08% at 19,639.

The top three NYSE percentage gainers premarket .PRPG.NQ:
** Brookfield Business Partners LP BBU.N, up 13.2%
** Allurion Technologies ALUR.N, up 5.9%
** Perfect Corp PERF.N, up 5.9%

The top three NYSE percentage losers premarket .PRPL.NQ:
** Abercrombie & Fitch Co ANF.N, down 9.4%
** Foot Locker Inc FL.N, down 8.7%
** Pvh Corp PVH.N, down 8.4%

The top Nasdaq percentage gainer premarket .PRPG.O:
** Bolt Projects Holdings Inc BSLK.O, up 105.3%

The top two Nasdaq percentage losers premarket .PRPL.O:
** Agape Atp Corp ATPC.O, down 17.7%
** Arbuthnot Banking Group PLC ARBB.O, down 16.8%


** SentinelOne Inc S.N: up 3.8% premarket
BUZZ - Climbs as higher client spending prompts upbeat forecast nL4N3KF0MD


** nCino Inc NCNO.O: down 14.1% premarket
BUZZ - Slides after unchanged annual revenue forecast nL4N3KF0P0


** Coinbase Global Inc COIN.O: down 1.9% premarket
** Riot Platforms Inc RIOT.O: down 1.4% premarket
** Marathon Digital Holdings Inc MARA.O: down 2.4% premarket
** Hut 8 Mining Corp HUT.O: down 2.0% premarket
BUZZ - Crypto stocks fall in tandem with bitcoin nL4N3KF0PZ


** Newmont Corp NEM.N: down 1.2% premarket
** Barrick Gold Corp GOLD.N: down 1.5% premarket
** Gold Fields Ltd GFI.N: down 2.7% premarket
** AngloGold Ashanti Ltd AU.N: down 3.6% premarket
BUZZ - Gold miners decline after bullion falls 1% nL4N3KF11H


** PVH Corp PVH.N: down 8.4% premarket
BUZZ - Drops after downbeat Q3 forecasts nL4N3KF0ST


** Semtech Corp SMTC.O: up 6.3% premarket
BUZZ - Gains on upbeat forecast, Q2 results beat nL4N3KF0TT


** Ambarella Inc AMBA.O: up 20.1% premarket
BUZZ - Soars after Q3 revenue forecast above estimates nL4N3KF0S4


** Foot Locker Inc FL.N: down 8.7% premarket
BUZZ - Drops as co posts wider Q2 loss, reaffirms annual forecasts nL4N3KF0UX


** Kohl's Corp KSS.N: up 1.3% premarket
BUZZ - Jumps on raising annual profit forecast nL4N3KF0WG


** Patterson Companies Inc PDCO.O: down 8.5% premarket
BUZZ - Tumbles on Q1 profit miss nL4N3KF0XX


** Nanobiotix SA NBTX.O: up 4.3% premarket
BUZZ - Guggenheim initiates Nanobiotix coverage with 'buy', shares rise nL4N3KF0XN


** Bath & Body Works Inc BBWI.N: down 3.5% premarket
BUZZ - Down after annual profit, sales forecast cut nL4N3KF0XF


** Chewy Inc CHWY.N: up 2.4% premarket
BUZZ - Rises on Q2 profit beat nL4N3KF0Y6


** Starwood Property Trust Inc STWD.N: up 0.6% premarket
BUZZ - Raymond James raises Starwood Property Trust PT nL4N3JV1OA


** J.M. Smucker Co SJM.N: down 4.3% premarket
BUZZ - Down on trimming annual sales, profit forecasts nL4N3KF0ZH


** Abercrombie & Fitch Co ANF.N: down 9.4% premarket
BUZZ - Pares YTD gains after Q2 results nL4N3KF0ZS


** 23andMe Holdings Co ME.O: up 6.8% premarket
BUZZ - Unit to offer GLP-1 medication through weight loss program, shares rise nL4N3KF106


** Maravai LifeSciences Holdings Inc MRVI.O: up 3.0% premarket
BUZZ - Climbs on collaboration to launch DNA concentration testing kit nL4N3KF11L


** Exxon Mobil Corp XOM.N: down 0.4% premarket
** Chevron Corp CVX.N: down 0.4% premarket
** Marathon Oil Corp MRO.N: down 0.6% premarket
** SM Energy Co SM.N: down 1.1% premarket
BUZZ - Oil companies fall as demand concerns offset supply risks nL4N3KF117


** Ocugen Inc OCGN.O: up 1.5% premarket
BUZZ - Rises on completing patient dosing in early-stage gene therapy trial nL4N3KF0XG


(Compiled by Rajarshi Roy and Pooja Menon in Bengaluru)

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.